Consistent expansion of the pharmaceutical and biotechnology sectors along with the surging need for therapeutic drugs will positively bolster the bioreactors market. The increasing prevalence of cancer has led to higher demand and production of monoclonal antibodies. Also, the influx of bioprocessing equipment has resulted in the influx of the latest technologies.

The surging cases of the COVID-19 infection worldwide have affected millions of people and are causing increasing casualties, due to the community transmission in some regions. This has fueled the incessant need for vaccines and other biologics to control the mortality rate. Taking note of this, numerous biopharma and biotech companies together with government support are working on proliferating the R&D activities for COVID-19 vaccines. The pandemic has also attracted multiple growth opportunities for bioreactor manufacturers to meet the higher demand and mass production.

Request for a sample copy of this report @ https://www.decresearch.com/request-sample/detail/141   

It has been reported that the global bioreactors market size will register a substantial annual remuneration by 2027.

Revenue from single-use bioreactors will reach more than 20.2% CAGR through 2027. This is owing to their increasing adoption as they are affordable and offer minimum cross-contamination, as well as higher flexibility and productivity.

Increasing preference for multi-drug facilities has also resulted in various innovations by leading participants. For instance, in December 2020, Thermo Fisher Scientific, introduced HyPerforma DynaDrive, a single-use bioreactor to offer enhanced performance and scalability for cell culture production.

Demand for yeast cells will gain significant prominence through 2027 due to their higher usage in the manufacturing of protein based as well as other fermented products. There is also a rising adoption of flocculation bioreactors as they impart high cell density and productivity in continuous processes. This has urged their need in controlling yeast flocculation.

Bioreactors industry size from the stem cells molecule segment crossed USD 210 million in 2020 owing to the increasing cases of cancer across the globe. Stem cells are widely used to replace damaged cells in the body and strengthen the donor's immune system to counter cancer and other disorders. They are hence excessively used in stem cell therapies and various treatment methods to cure heart disorders and neuromuscular diseases. Furthermore, the rising government support and the surge in R&D spending by companies will enhance the adoption of cell-based products.

Request for customization @ https://www.decresearch.com/roc/141

The revenue share of bioreactors through commercial production is expected to rise at a 15.3% CAGR up to 2027. This can be owed to the increasing need for bioreactors in the mass production of biologics to cater to the rising requirement across the pharmaceutical and biotechnology sectors. They are also widely used across the healthcare industry to process biological materials with the help of agents like cells, enzymes, or antibodies.

Contract manufacturing organizations (CMOs) are pegged to contribute a substantial revenue for bioreactors in the next few years due to their increasing popularity across the healthcare sector to outsource developed products. These facilities are cost-effective and work closely with leading industry participants to help them establish their footprint across emerging nations. They are also used by major biotechnology companies that are largely focused on marketing. Also, firms with improper infrastructure and technical expertise outsource to CMOs, further complimenting the adoption of the bioreactors across these centers.

Asia Pacific accounted for over 20% of the bioreactors market share in 2020 and will register significant gains owing to the incorporation of advanced technologies and the strong presence of healthcare firms that have higher manufacturing capacities. There is increasing government support in the form of healthcare and R&D investments. Besides, various business opportunities, such as innovations and collaborations between the regional and international pharma companies will boost the consumption of bioreactors across the continent.

Partial Chapter of the Table of Content:

Chapter 2   Executive Summary

2.1    Bioreactors industry 360⁰ synopsis, 2016 – 2027 (USD Million)

2.1.1    Business trends

2.1.2    Product type trends

2.1.3    Cell trends

2.1.4    Molecule trends

2.1.5    Usage trends

2.1.6    End-use trends

Browse complete Table of Contents (ToC) of this research report @ https://www.decresearch.com/toc/detail/bioreactor-market